View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondar...

Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild or moderate COVID-19 patients were enrolled and treated with OVYDSO™ (Olgotrelvir) or placebo. The primary endpoint was time to sustained recovery of 11 COVID-19 related symptoms and the key secondary endpoint was the viral RNA copy load reduction.Ovydso significantly shortened...

 PRESS RELEASE

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Resul...

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients All study objectives were met, demonstrating safety across dose groups and confirming efficacy and durability at the selected doses against placebo (lidocaine) and active control (steroid).All RTX doses (7.5 to 20 µg) were well-tolerated, with few severe or serious adverse events (AEs). The majority of reported AEs related to pain post-administration and resolved within hours following treatment. Ver...

 PRESS RELEASE

Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests...

Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, it has posted a “Frequently Asked Questions” (FAQ) document in response to a number of requests from parties who hold short interests in restricted stock ...

 PRESS RELEASE

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for...

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study Abivertinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor that irreversibly targets BTK. BTK inhibitors are a large category in cancer treatment, with multiple indications and generating over $10.6 billion per year revenue in 2022.In this phase IIa study conducted in China, a total of 27 R/R MZL patients treated with Abivertinib were assessed and the overall response rate (ORR) was 59.3 % (16/27 patient...

 PRESS RELEASE

Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial wi...

Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19 The Phase 3 study of Ovydso was initiated in China in February 2023 and enrolled and dosed 1,200 COVID-19 patients (1:1, active:placebo) at 25 sites in China.During the trial, Ovydso has maintained an excellent safety profile with no Grade 3 toxicities reported.We anticipate top line data in the third quarter of this year.If the trial meets its endpoints, we have agreements with the China Health Authority ...

 PRESS RELEASE

Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government c...

Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded a $4.6 million contract from the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health (NIH) for the development of in vitro diagnostics for biodefense, antimicrobial resistant infections and emerging infectious diseases. The award shows NI...

 PRESS RELEASE

Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharm...

Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Shanghai Escugen Biotechnology Co., Ltd. (“Escugen”), a partner of Levena (Suzhou) Biopharma Co., Ltd. (“Levena”), a wholly owned subsidiary of Sorrento Therapeutics, Inc. (Sorrento), today released preliminary results from a first-in-human study of ESG401, a trophoblast cell-su...

 PRESS RELEASE

Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Reg...

Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”) SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company (“Scilex”) previously held by Sorrento. The Form 8937 has be...

 PRESS RELEASE

Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Di...

Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”) SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an update to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento (the “Dividend Stock”). The update to the FAQs provides notice regarding the no lie...

 PRESS RELEASE

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Comp...

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc. SAN DIEGO and PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements: Henry Ji, P...

 PRESS RELEASE

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therap...

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1   The acute migraine drug market size is expected to reach US$9.26 billion by 2030.3There is strong evidence for use of NSAIDs as first-line treatment for migraine, and celecoxib is in same class of agents, fast acting and has the potential to have the l...

 PRESS RELEASE

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therap...

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders PALO ALTO, Calif., Feb. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that its first virtual-only Annual Meeting of Stockholder...

 PRESS RELEASE

Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage...

Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today distributed dividend confirmation statements to 146 brokerage firms regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) held by Sorrento. These statements, which contain the account numbers ...

 PRESS RELEASE

Sorrento Issues Supplement to its Previously Issued “FAQ” Regarding th...

Sorrento Issues Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a supplement to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation’s remova...

 PRESS RELEASE

Scilex Holding Company Announces that its Majority Stockholder, Sorren...

Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock PALO ALTO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a supplement to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at regarding its recent dividend to Sorrento stockholders of sh...

 PRESS RELEASE

Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company...

Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock SAN DIEGO, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a “Frequently Asked Questions” document under the “Investors” section of its website at regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The FAQs address questions regarding the details of the dividend, including the record date, payment date, dividend ratio, distribution of the shares of Scilex common stock, how S...

 PRESS RELEASE

Scilex Holding Company Announces that its Majority Stockholder, Sorren...

Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock PALO ALTO, Calif., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a “Frequently Asked Questions” document under the “Investors” section of its website at regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento. The F...

 PRESS RELEASE

Sorrento Releases Positive Results from a Phase 1b Study in China in C...

Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single ascending dose (SAD) portion of the study with the doses from 300 mg to 2,000 mg in 32 healthy volunteers and the multiple ascending dose (MAD) portion of the study in 46 COVID-19 patients with 300 mg BID, 600 mg ...

 PRESS RELEASE

Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical ...

Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus Modified mRNA sequence of the Spike protein prevents cleavage of the expressed protein, which may potentially result in a cleaner safety profile.Pre-clinical data supporting the investigational new drug application has been published in Molecular Therapy Nucleic Acids, a Cell Press Journal ().If approved, this vaccine may provide an important alternative to the vaccines in the U.S. and enable improved access globally in countries like M...

 PRESS RELEASE

Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhib...

Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO) IMC-001, a PD-L1 monoclonal antibody selected from Sorrento’s G-MAB library, demonstrated impressive therapeutic effects in patients with heavily treated NK/T-cell lymphoma with a 60% objective response rateAchieved 100% complete remission in patients with an objective response rateLong-term safety and durable response are demonstrated in patients who continued on treatment for over a year SAN DIEGO, Dec. 05, 2022 (GLOBE NEWS...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch